Cocrystal Pharma (NASDAQ:COCP) Trading Down 2.1% – Here’s Why

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s stock price fell 2.1% during mid-day trading on Monday . The company traded as low as $0.93 and last traded at $0.93. 16,486 shares changed hands during trading, a decline of 63% from the average daily volume of 44,991 shares. The stock had previously closed at $0.95.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Cocrystal Pharma Stock Performance

The company has a market capitalization of $12.82 million, a PE ratio of -1.27 and a beta of 1.41. The company’s 50-day simple moving average is $1.05 and its 200-day simple moving average is $1.11.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.23 million. Analysts expect that Cocrystal Pharma, Inc. will post -0.69 EPS for the current year.

Hedge Funds Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.